Similarly, transformation of NSCLC to SCLC in patients receiving PD-1/PD-L1 inhibitors has been reported as a mechanism of resistance to PD-1/PD-L1 inhibitors (12–15). Here, PDCD1 is linked to non-small cell lung carcinoma.